Patents by Inventor Bent Nørgaard-Pedersen

Bent Nørgaard-Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADAM12, A NOVEL MARKER FOR ABNORMAL CELL FUNCTION
    Publication number: 20100190174
    Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.
    Type: Application
    Filed: February 2, 2010
    Publication date: July 29, 2010
    Inventors: Ulla M. Wewer, Bent Nørgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Fröhlich
  • ADAM12, a novel marker for abnormal cell function
    Patent number: 7678544
    Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: March 16, 2010
    Assignees: Statens Serum Institut, Kobenhavns Universitet, Harold Wood Hospital
    Inventors: Ulla M. Wewer, Bent Nørgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Fröhlich, Kevin Spencer